DFDA

Topical Lidocaine (5% patch)

Treatment for Peripheral Neuropathy

Typical Dosage: Up to 3 patches for up to 12 hours/day

Effectiveness
60%
Safety Score
85%
Clinical Trials
7
Participants
9K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
Up to 3 patches for up to 12 hours/day
Time to Effect
30 minutes to 2 hours
Treatment Duration
Applied daily as needed
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,400
Monitoring:$150
Side Effect Mgmt:$20
Total Annual:$2,570
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$35,000/QALY
QALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$6,763.16
Cost per Remission
$128,500
Prescription Access Economics
Annual Societal Loss per Patient
$1,247.5
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$375/year
Time Cost
$112.5/year
Travel + wait time
Insurance Admin Cost
$60/year
Prior auth, claims
Rx Price
$2,400/year
Potential OTC Price
$1,200/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Topical Lidocaine (5% patch) Outcomes

for Peripheral Neuropathy

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+38%
Remission Rate
+2%
Common Side Effects
Application site erythema
+8%
Application site edema
+5%
Application site pruritus
+5%

Sources:

nih.gov
england.nhs.uk
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Topical Lidocaine (5% patch) in Peripheral Neuropathy

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593NOT YET RECRUITINGPHASE4
View Study
600 participants
INTERVENTIONAL
Stanford, United States +22 more
Started: Sep 1, 2026
Completed Clinical Trials
4 completed trials for Topical Lidocaine (5% patch) in Peripheral Neuropathy

Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

NCT01086150COMPLETEDPHASE2, PHASE3
View Study
51 participants
INTERVENTIONAL
Albany, United States
Started: Oct 1, 2009

Symptom Management After Breast Cancer Surgery

NCT00686127COMPLETEDPHASE4
View Study
21 participants
INTERVENTIONAL
San Francisco, United States
Started: Sep 1, 2003

Topical Lidocaine: Predictors of Response in Peripheral Nerve Injury

NCT01112748COMPLETEDPHASE4
View Study
24 participants
INTERVENTIONAL
Aarhus C, Denmark
Started: Apr 1, 2010

A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin

NCT03587220COMPLETEDNA
View Study
44 participants
INTERVENTIONAL
Aalborg, Denmark
Started: Aug 1, 2018